An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs CPI 613 (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Rafael Pharmaceuticals
- 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
- 27 Dec 2016 Status changed from recruiting to discontinued.
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.